{"id":7259,"date":"2005-06-15T11:23:45","date_gmt":"2005-06-15T10:23:45","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=7259"},"modified":"2014-05-21T17:50:40","modified_gmt":"2014-05-21T17:50:40","slug":"application-for-meltrex-formulation-of-kaletra-submitted-to-the-fda","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/7259","title":{"rendered":"Application for meltrex formulation of Kaletra submitted to the FDA"},"content":{"rendered":"<p><strong>Abbott announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) of a new formulation of Kaletra (lopinavir\/ritonavir).<\/strong><\/p>\n<p>The tablet was developed using a proprietary novel melt-extrusion technology intended to allow patients to take fewer tablets per dose as part of their treatment regimen. In addition, the tablet would not require refrigeration, as the current soft-gel capsule formulation does.<\/p>\n<p>The new tablet will provide patients with a tablet composed of 200 mg lopinavir and 50 mg ritonavir, which will reduce daily pill count to 4 tablets daily (standard current dose is 6 capsules). The submission package included data from bioequivalence studies.<\/p>\n<p>Source: Abbott Press Release, May 2005<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbott announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) of a new formulation of Kaletra (lopinavir\/ritonavir). The tablet was developed using a proprietary novel melt-extrusion technology intended to allow &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-7259","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=7259"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7259\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=7259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=7259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=7259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}